FDA announces recall of infusion pumps after thousands of complaints, 1 death

InfuTronix has recalled its Halo Ambulatory Infusion System and several Nimbus pumps after 3,698 complaints and one death, attributed to device failures. Due to a serious risk of medication overdoses and patient dehydration, the U.S. Food and Drug Administration (FDA) has identified this as a Class I recall, the most serious type.

The infusion systems are used in hospitals and healthcare facilities, but are often also used at-home for patients to distribute their own pain medication. Malfunctions in the systems—ranging from battery failures to line blockages—can cause serious adverse health events, including seizures and death.

InfuTronix sent customers an Urgent Medical Device Removal letter in February, recommending use of the recalled systems cease immediately as part of their larger removal from the market.

All recalled devices will no longer be available or supported after June 20, 2024.

What is being recalled?

A total of 52,328 systems released between February 27, 2015 and February 29, 2024 are subject to the urgent recall. The specific product codes for affected devices can be found by clicking the links below:

These infusion pumps and systems are used to administer medications subcutaneously, intradermally, intrathecally and intravenously. In its notice, the FDA warns use of the above products “may lead to serious injury or death.”

Next Steps

Any provider or patient in possession of any of the recalled infusion systems is being instructed to contact InfuTronix at Customerservice@intuvie.com to initiate a return.

Providers are being asked to seek alternatives for patients immediately, as soon as a safe system can be acquired for their patients.

The full FDA recall notice can be found here.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.